{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T01:32:15Z","timestamp":1723685535863},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/grf.0b013e31827af770","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T17:30:46Z","timestamp":1357839046000},"page":"10-16","source":"Crossref","is-referenced-by-count":9,"title":["Development and Impact of Human Papillomavirus Vaccines"],"prefix":"10.1097","volume":"56","author":[{"given":"CHRISTOPHER J.","family":"DARUS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JENNIFER J.","family":"MUELLER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210126","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-4-20210126","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/hv.7.2.13690","article-title":"Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines.","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccin"},{"key":"R5-4-20210126","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-4-20210126","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"R7-4-20210126","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18.","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"R9-4-20210126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-1618 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"R10-4-20210126","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1086\/597308","article-title":"Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.","volume":"199","author":"Herrero","year":"2009","journal-title":"J Infect Dis"},{"key":"R11-4-20210126","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4161\/hv.3.4.4058","article-title":"Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.","volume":"3","author":"Smith","year":"2007","journal-title":"Hum Vaccin"},{"key":"R12-4-20210126","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"key":"R13-4-20210126","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6111618 vaccine: a combined analysis of five randomized controlled trials.","volume":"114","author":"Garland","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R14-4-20210126","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-1618 AS04-adjuvanted vaccine: up to 8.4 years of follow-up.","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R15-4-20210126","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"R16-4-20210126","first-page":"S3178","article-title":"Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes.","volume":"24","author":"Garnett","year":"2006","journal-title":"Vaccine"},{"key":"R17-4-20210126","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1071\/SH10018","article-title":"A brief history of economic evaluation for human papillomavirus vaccination policy.","volume":"7","author":"Beutels","year":"2010","journal-title":"Sex Health"},{"key":"R18-4-20210126","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1016\/j.vaccine.2008.04.053","article-title":"Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.","volume":"26","author":"Goldie","year":"2008","journal-title":"Vaccine"},{"key":"R19-4-20210126","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States.","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"key":"R20-4-20210126","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0968-8080(08)32409-4","article-title":"Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.","volume":"16","author":"Goldie","year":"2008","journal-title":"Reprod Health Matters"},{"key":"R21-4-20210126","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00038-010-0216-6","article-title":"A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.","volume":"56","author":"Demarteau","year":"2011","journal-title":"Int J Public Health"},{"key":"R22-4-20210126","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.arcmed.2009.06.003","article-title":"The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change.","volume":"40","author":"Franco","year":"2009","journal-title":"Arch Med Res"},{"key":"R23-4-20210126","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.arcmed.2009.08.005","article-title":"Advantages and disadvantages of current prophylactic vaccines against HPV.","volume":"40","author":"Madrid-Marina","year":"2009","journal-title":"Arch Med Res"},{"key":"R24-4-20210126","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(09)62029-8","article-title":"Gardasil: from bench, to bedside, to blunder.","volume":"375","author":"Bach","year":"2010","journal-title":"Lancet"},{"key":"R25-4-20210126","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa0808516","article-title":"HPV screening for cervical cancer in rural India.","volume":"360","author":"Sankaranarayanan","year":"2009","journal-title":"N Engl J Med"},{"key":"R26-4-20210126","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.vaccine.2009.12.042","article-title":"Determinants for HPV vaccine uptake in the Netherlands: a multilevel study.","volume":"28","author":"Rondy","year":"2010","journal-title":"Vaccine"}],"container-title":["Clinical Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003081-201303000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T01:55:47Z","timestamp":1618365347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003081-201303000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0b013e31827af770","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}